scholarly journals Quantitative Susceptibility Mapping-Derived Radiomic Features in Discriminating Multiple Sclerosis From Neuromyelitis Optica Spectrum Disorder

2021 ◽  
Vol 15 ◽  
Author(s):  
Zichun Yan ◽  
Huan Liu ◽  
Xiaoya Chen ◽  
Qiao Zheng ◽  
Chun Zeng ◽  
...  

Objectives: To implement a machine learning model using radiomic features extracted from quantitative susceptibility mapping (QSM) in discriminating multiple sclerosis (MS) from neuromyelitis optica spectrum disorder (NMOSD).Materials and Methods: Forty-seven patients with MS (mean age = 40.00 ± 13.72 years) and 36 patients with NMOSD (mean age = 42.14 ± 12.34 years) who underwent enhanced gradient-echo T2*-weighted angiography (ESWAN) sequence in 3.0-T MRI were included between April 2017 and October 2019. QSM images were reconstructed from ESWAN, and QSM-derived radiomic features were obtained from seven regions of interest (ROIs), including bilateral putamen, globus pallidus, head of the caudate nucleus, thalamus, substantia nigra, red nucleus, and dentate nucleus. A machine learning model (logistic regression) was applied to classify MS and NMOSD, which combined radiomic signatures and demographic information to assess the classification accuracy using the area under the receiver operating characteristic (ROC) curve (AUC).Results: The radiomics-only models showed better discrimination performance in almost all deep gray matter (DGM) regions than the demographic information-only model, with the highest AUC in DN of 0.902 (95% CI: 0.840–0.955). Moreover, the hybrid model combining radiomic signatures and demographic information showed the highest discrimination performance which achieved the AUC of 0.927 (95% CI: 0.871–0.984) with fivefold cross-validation.Conclusion: The hybrid model based on QSM and powered with machine learning has the potential to discriminate MS from NMOSD.

2021 ◽  
Vol 51 ◽  
pp. 102886
Author(s):  
Ricardo Alonso ◽  
Berenice Silva ◽  
Orlando Garcea ◽  
Patricio E. Correa Diaz ◽  
Giordani Rodrigues dos Passos ◽  
...  

2018 ◽  
Vol 25 (11) ◽  
pp. 1452-1461 ◽  
Author(s):  
Shanthi Viswanathan ◽  
Lee Mei Wah

Objectives: This study looked at observed crude prevalence/incidence of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) in Malaysia and identified any inter-ethnic differences for MS/NMOSD. Methods: This was a nationwide tertiary hospital–based retrospective cross-sectional study using the capture–recapture method. It looked at the estimated crude prevalence of confirmed MS and NMOSD and annual incidence on 29 December 2017. Recapture of data was done between February and March 2018 on 1 March 2018. Public and referring private institutions were accessed. Results: The survey identified 767 MS and 545 NMOSD subjects, with crude prevalence rates of 2.73 per 100,000 (95% confidence interval (CI): 2.53; 2.92 per 100,000 population) and 1.94 per 100,000 (95% CI: 1.77; 2.10 per 100,000 population) with observed crude annual incidence of 0.55 (95% CI: 0.43; 0.58) for MS and 0.39 per 100,000 (95% CI: 0.35; 0.47) for NMOSD. The MS:NMOSD ratios were 1.4:1.0. The capture–recapture method revealed 913 MS (95% CI: 910; 915.9) and 580 (95% CI: 578.8; 581.2) NMOSD with prevalence per 100,000 of 3.26 (95% CI: 3.05; 3.47) and 2.07 (95% CI: 1.90; 2.24), respectively. In the MS group, 59.4% were Malay, 16.6% Chinese, 20.5% Indian, and 3.5% were from indigenous groups. In the NMOSD group, 47.3% were Malay, 46.9% Chinese, 3.5% Indian, and 2.3% were from other indigenous groups. The ratio of NMOSD to MS among the Chinese was 2:1, but the ratio of MS to NMOSD among the Malays was 1.8:1, and that in Indians was 8.3:1. Conclusion: There is a modest increase in the prevalence of MS and NMOSD in Malaysia with inter-ethnic differences for MS/NMOSD.


2021 ◽  
Vol 27 ◽  
Author(s):  
Paulus Rommer ◽  
Uwe K Zettl

: There are few diseases with as many therapeutic advances in recent years as in multiple sclerosis. Nine different drug classes with more than a dozen approved therapies are now available. Similarly, there have been unimaginable advances in understanding neuromyelitis optica (now neuromyelitis optica spectrum disorder [NMOSD]) over the past 15 years. Building on the knowledge gained, the first therapies have been approved in recent years. In this review, we aim to present all therapies approved for the treatment of MS or NMOSD. The different forms of application, different approval criteria and most important side effects will be presented. This work is intended for physicians who are interested in MS and NMOSD therapies and want to get a first overview and does not replace the respective guidelines of the regulatory authorities.


PLoS ONE ◽  
2020 ◽  
Vol 15 (4) ◽  
pp. e0224419
Author(s):  
Hiroki Masuda ◽  
Masahiro Mori ◽  
Akiyuki Uzawa ◽  
Tomohiko Uchida ◽  
Ryohei Ohtani ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document